Tasly Pharmaceutical Group (600535.SH) released its performance for the year 2024, with a year-on-year decrease in net profit of 10.78% to 956 million RMB, and plans to distribute 2 RMB per 10 shares.

Tasly Pharmaceutical Group (600535.SH) released its annual report for 2024, reporting a total operating income of 8.498 billion yuan, a decrease of 2.03% year-on-year; a net profit attributable to shareholders of the listed company of 956 million yuan, a decrease of 10.78% year-on-year; a net profit attributable to shareholders of the listed company excluding non-recurring profits and losses of 1.036 billion yuan, a decrease of 12.31% year-on-year; and basic earnings per share of 0.64 yuan per share. The company plans to distribute profits based on the total capital stock registered on the equity distribution registration date for 2024. According to the proposal of the board of directors, it is proposed to distribute a cash dividend of 2 yuan (tax included) to all shareholders for every 10 shares. The main factors driving the company's performance during the reporting period are as follows: first, focusing on world-leading targets and cutting-edge technologies, adhering to innovation and self-renewal, increasing research and development innovation, improving research and development quality, accelerating the innovation and transformation of modern Chinese medicine, upgrading the business capabilities of the innovative platform through integrated management, and consolidating the leading position in modern Chinese medicine; second, promoting multiple products to be included in the "National Medical Insurance Directory," "National Drug Centralized Procurement," and various clinical guidelines and expert consensus, actively promoting the landing and implementation of national medical insurance negotiation varieties and national drug centralized procurement varieties. Taking product academic promotion as the basic means, continuously deepening the scientific content of products, enhancing the integration of diagnosis and treatment medical service systems, and improving product coverage at all levels of end terminals through conveying the core brand value and clinical benefits of products; third, continuously promoting lean production and intelligent manufacturing, continuously improving digitalization of processes, quality standards, and production processes, aiming for quality and efficiency, integrating digital technology throughout the drug lifecycle, and forming a smart manufacturing system with modern Chinese medicine at its core; fourth, combining production and investment to cultivate new growth drivers and create a new value system through ecological integration, the company is based on large biopharmaceuticals, accelerating the cultivation of new profit growth points.